AL3810 is predicted to bind to the kinase domain of VEGFR2, but Sorafenib may prefer to bind to the hydrophobic region besides to the kinase domain, in Figure 2D. Furthermore, in all in vivo xenograft models, the significant growth inhibition of AL3810 was achieved at doses of 10 mg/kg (daily p.o.)whereas the comparable anti-tumour efficacy of sorafenib, required six-fold higher dosage. This evidence concerns the gene KDR and neoplasm.